-
-
In a review of nine Phase 3 trials enrolling 6,284 patients, data from 793 who were younger than 50 years old were compared to the remainder who were older than 50 years, with attention given to progression-free survival, response rates, and overall survival.
-
A 78-year-old man was referred for evaluation and treatment of recently discovered glioblastoma. While dining with his children he collapsed from his chair and was observed to have a grand mal seizure. He had transiently lost consciousness and when he awoke he had weakness in both upper and lower extremities on the right side.
-
FDA issues multiple drug safety alerts; ARBs and cancer risk; and FDA actions.
-
The use of sunlamps or sunbeds for tanning purposes has grown in popularity, such that their use is very common among teenagers and young adults. In a well-conducted Australian multicenter, case-controlled study, it is clear that such use among teenagers is associated with a significantly higher risk of cutaneous melanoma. In fact, the risk is higher than it is for middle-aged sunbed users.
-
ACEI/ARB therapy for AS; safety alert issued for dronedarone; statins and cancer risk; nesiritide and heart failure; and FDA actions.
-
A 57-year-old, postmenopausal African American schoolteacher was found by annual screening mammogram to have a suspicious irregularity. Follow-up ultrasound did not reveal cystic disease so a repeat "spot" mammogram-assisted biopsy was obtained and a grade 1 invasive ductal carcinoma with tubular elements was found.
-
Preclinical data suggest bortezomib and rituximab have synergy for mantle cell lymphoma (MCL). The authors studied bortezomib, rituximab, and dexamethasone in relapsed and refractory MCL using 1.3 mg/m2 of bortezomib on days 1, 4, 8, and 11 with rituximab on day 1 and 40 mg of dexamethasone on days 1-4.
-
-
In a retrospective analysis of risk factors for the development of cerebral metastases in patients with known metastatic breast cancer, several factors including ER, HER-2, patient age, and site of first metastatic recurrence were found to be predicted. Using a cumulative incidence model employing competing-risk regression analysis, small initial tumor size, and the absence of metastatic disease at the time of diagnosis appeared to be independent risk factors.